Table 2.
Epidemiological Data Used in the Model‡
| Population | Men | Women | |
|---|---|---|---|
| Prevalence of MS [P(MS)] * | 150 | 71.4 | 228.6 |
| MZ twin Concordance (CRMZ) * | 25% | 6.5% | 34.0% |
| Raw% Susceptible [P(MS)]/CRMZ)* | 0.6% | 1.1% | 0.7% |
| Corrected% Susceptible** | 1.1% | 2.0% | 1.3% |
| % HLA DRB1*1501 (General Population) * | 24% | ||
| % HLA DRB1*1501 (MS Population) * | 55% | ||
| Homozygous DRB1*1501 (General Population) † | 1.6% | ||
| Homozygous DRB1*1501 (MS Population)† | 10.0% | ||
‡ For estimated recurrence risks in 1st, 2nd, and 3rd degree relatives; see Table 12
For estimated recurrence risk in HLA DRB1*1501 positive and negative patients; see Table 3.
* From Canadian Data [11], based on prevalence of 150/100,000 population [16] and split into men and women according to [17]. HLA data: D Sadovnick (personal communication)
** Percent of the population genetically susceptible to susceptible to MS [P(MS)]/CRMZ] corrected (see text) for the reported [11] difference in concordance risk for DZ twins (5.4%) and non-twin siblings (2.9%)
† UCSF Database: J Oksenberg (personal communication)